AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9437205 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral arginine HCl (8.4 g/d) administered to HC subjects for 2 weeks
Number of subjects: 0
Study 9437205 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment in HC subjects
Number of subjects: 0
Study 8466428 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebox (0 to 300 microA)
Number of subjects: 16
Study 8466428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30773553 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital occlusal splint (experimental group)
Number of subjects: 24
Study 30773553 — intervention group
Group type: COMPARATOR
Intervention: Traditional soft occlusal splint (control group)
Number of subjects: 24
Study 29589500 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-coated sutures
Number of subjects: 2546
Study 29589500 — intervention group
Group type: COMPARATOR
Intervention: Standard sutures
Number of subjects: 2546
Study 27669680 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone (8 μg b.d.)
Number of subjects: 505
Study 27669680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 505
Study 23550786 — intervention group
Group type: EXPERIMENTAL
Intervention: External focus of attention (image of the achievement)
Number of subjects: 36
Study 23550786 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal focus of attention (image of the act)
Number of subjects: 36
Study 23550786 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 23550786 — intervention group
Group type: EXPERIMENTAL
Intervention: External focus of attention
Number of subjects: 36
Study 23433435 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (40 mg/m² weekly for 6 weeks)
Number of subjects: 268
Study 23433435 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (250 mg/m² weekly with a loading dose of 400 mg/m² for 6 weeks)
Number of subjects: 268
Study 23433435 — intervention group
Group type: COMPARATOR
Intervention: Standard RT (elective RT up to 54.25 Gy with SIB to 70 Gy in 35 fractions over 6 weeks)
Number of subjects: 268
Study 23433435 — intervention group
Group type: EXPERIMENTAL
Intervention: Redistributed adaptive RT (elective RT up to 54.25 Gy with SIB between 64-80 Gy in 35 fractions over 6 weeks)
Number of subjects: 268
Study 23433435 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of median (89)Zr-Cetuximab uptake and biological markers with treatment specific outcome
Number of subjects: 268
Study 23433435 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxicity assessment
Number of subjects: 268
Study 23433435 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 268
Study 23433435 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowing function preservation
Number of subjects: 268
Study 23433435 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression free survival
Number of subjects: 268
Study 23433435 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 268
Study 21175446 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant (125 mg)
Number of subjects: 30
Study 21175446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 18971537 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (25-100 mg)
Number of subjects: 65
Study 18971537 — intervention group
Group type: COMPARATOR
Intervention: Calcium Channel Blocker (CCB)
Number of subjects: 65
Study 16649855 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitudes based on behaviorally relevant knowledge
Number of subjects: 0
Study 16649855 — intervention group
Group type: EXPERIMENTAL
Intervention: Complexity of knowledge
Number of subjects: 0
Study 16649855 — intervention group
Group type: EXPERIMENTAL
Intervention: High-behavioral relevance knowledge
Number of subjects: 0
Study 16649855 — intervention group
Group type: EXPERIMENTAL
Intervention: Amount of knowledge
Number of subjects: 0
Study 16649855 — intervention group
Group type: EXPERIMENTAL
Intervention: Complexity effect
Number of subjects: 0
Study 14636806 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathways intervention (classroom curriculum, food service, physical activity, and family modules)
Number of subjects: 1704
Study 14636806 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathways intervention
Number of subjects: 1704
Study 14636806 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1704
Study 10946911 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvisomant 30 mg or 80 mg weekly for 6 weeks
Number of subjects: 6
Study 10946911 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvisomant 10‐20 mg/d for 12 weeks
Number of subjects: 6
Study 10946911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8836654 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 200, 375 and 1,000 micrograms b.i.d.
Number of subjects: 21
Study 8836654 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 200, 400 and 1,000 micrograms b.i.d.
Number of subjects: 21
Study 8836654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 1477853 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium pidolate (15 mmol/day)
Number of subjects: 14
Study 1477853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 7192153 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (paracetamol) 1000 mg
Number of subjects: 108
Study 7192153 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone 10 mg
Number of subjects: 108
Study 7192153 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of acetaminophen plus hydrocodone
Number of subjects: 108
Study 7192153 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 60 mg
Number of subjects: 108
Study 7192153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 31439684 — intervention group
Group type: EXPERIMENTAL
Intervention: Early menopause (<45 years)
Number of subjects: 94742
Study 31439684 — intervention group
Group type: COMPARATOR
Intervention: Normal menopause (45-55 years)
Number of subjects: 94742
Study 31439684 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational analysis of early menopause
Number of subjects: 94742
Study 31439684 — intervention group
Group type: COMPARATOR
Intervention: Observational analysis of normal menopause
Number of subjects: 94742
Study 28133908 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-time point-based multimarker panel of biomarkers (NT-proBNP, hs-cTnT, sST2, GDF-15, cystatin-C, galectin-3, hs-CRP)
Number of subjects: 1161
Study 28133908 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat measurement of NT-proBNP and cystatin-C on day 2
Number of subjects: 1161
Study 28133908 — intervention group
Group type: EXPERIMENTAL
Intervention: Further measurements of hs-cTnT, GDF-15, sST2, and hs-CRP on days 14 and 60
Number of subjects: 1161
Study 28133908 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual biomarker additions on top of the baseline model
Number of subjects: 1161
Study 26556478 — intervention group
Group type: EXPERIMENTAL
Intervention: Font size (large vs small) for learners making JOLs
Number of subjects: 0
Study 26556478 — intervention group
Group type: COMPARATOR
Intervention: Font size (large vs small) for observers making JOLs
Number of subjects: 0
Study 26556478 — intervention group
Group type: EXPERIMENTAL
Intervention: Font size (large vs small) for participants making belief-based recall predictions
Number of subjects: 0
Study 24312277 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher HIV diversity in the pol region prior to ART initiation
Number of subjects: 139
Study 24312277 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 139
Study 21273927 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus DBS
Number of subjects: 0
Study 21273927 — intervention group
Group type: COMPARATOR
Intervention: Globus pallidus internus DBS
Number of subjects: 0
Study 21273927 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall DBS cohort
Number of subjects: 0
Study 18945924 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 14
Study 18945924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 17675592 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncompressed acoustic stimuli
Number of subjects: 60
Study 17675592 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporally compressed stimuli
Number of subjects: 60
Study 17675592 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporally expanded stimuli
Number of subjects: 60
Study 17675592 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency compressed and expanded conditions
Number of subjects: 60
Study 16600222 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral carnitine (2,000 mg L-carnitine and 1,000 mg L-acetyl-carnitine per day)
Number of subjects: 21
Study 16600222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 12686329 — intervention group
Group type: EXPERIMENTAL
Intervention: enoxaparin
Number of subjects: 141
Study 12686329 — intervention group
Group type: EXPERIMENTAL
Intervention: dalteparin
Number of subjects: 141
Study 12686329 — intervention group
Group type: COMPARATOR
Intervention: unfractionated heparin (UFH)
Number of subjects: 141
Study 10599875 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen (ITB) at doses of 25, 50, and 75 microg
Number of subjects: 8
Study 10599875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7862477 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary carrying intervention
Number of subjects: 210
Study 7862477 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased parental responsiveness intervention
Number of subjects: 210
Study 7862477 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 210
Study 2127046 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 24
Study 2127046 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition
Number of subjects: 24
Study 7295193 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary treatment (fat-controlled, low cholesterol diet)
Number of subjects: 99
Study 7295193 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibrate treatment
Number of subjects: 99
Study 7295193 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal blood lipid values)
Number of subjects: 99
Study 29773947 — intervention group
Group type: EXPERIMENTAL
Intervention: BFF MDI 320/9.6 μg
Number of subjects: 180
Study 29773947 — intervention group
Group type: EXPERIMENTAL
Intervention: BFF MDI 160/9.6 μg
Number of subjects: 180
Study 29773947 — intervention group
Group type: EXPERIMENTAL
Intervention: BFF MDI 80/9.6 μg
Number of subjects: 180
Study 29773947 — intervention group
Group type: COMPARATOR
Intervention: BD MDI 320 μg
Number of subjects: 180
Study 27521179 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printing technology (3DPT)
Number of subjects: 66
Study 27521179 — intervention group
Group type: COMPARATOR
Intervention: Thin-layer CT scan (control)
Number of subjects: 66
Study 25707610 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin/S-1
Number of subjects: 0
Study 25707610 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin/5-FU
Number of subjects: 0
Study 24386491 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) of the quadriceps, ideally daily sessions of 30 minutes, minimum three times weekly
Number of subjects: 49
Study 24386491 — intervention group
Group type: COMPARATOR
Intervention: Usual care without NMES
Number of subjects: 49
Study 20577660 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal system (BTDS) 5 microg/h to 20 microg/h
Number of subjects: 53
Study 20577660 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal system (BTDS)
Number of subjects: 53
Study 20577660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 19047364 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 2.5 microg
Number of subjects: 40
Study 19047364 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 5 microg
Number of subjects: 40
Study 19047364 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 10 microg
Number of subjects: 40
Study 19047364 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 15 microg
Number of subjects: 40
Study 19047364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15954961 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine (210 microg kg(‐1)) + Rocuronium (0.04 mg kg(‐1)) with 3-min priming interval
Number of subjects: 31
Study 15954961 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium (0.04 mg kg(‐1)) with 3-min sham priming
Number of subjects: 31
Study 15954961 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium (0.44 mg kg(‐1)) with 3-min sham priming
Number of subjects: 31
Study 15954961 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium (0.04 mg kg(‐1)) with 3-min priming and normal saline
Number of subjects: 31
Study 12772736 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% nitrogen exposure (anoxia)
Number of subjects: 9
Study 12772736 — intervention group
Group type: COMPARATOR
Intervention: Normal air exposure (control)
Number of subjects: 9
Study 10485352 — intervention group
Group type: EXPERIMENTAL
Intervention: Split virus vaccine
Number of subjects: 194
Study 10485352 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted subunit virus vaccine (SU/MF59)
Number of subjects: 194
Study 7573993 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 50
Study 7573993 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 50
Study 7573993 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia and General anesthesia
Number of subjects: 50
Study 1951567 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A (n = 32) - Incremental increases of oxytocin of 1 mU/min at 30‐minute intervals
Number of subjects: 80
Study 1951567 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol B (n = 48) - Incremental increases of oxytocin of 2 mU/min at 15‐minute intervals
Number of subjects: 80
Study 1951567 — intervention group
Group type: COMPARATOR
Intervention: Both protocols
Number of subjects: 80
Study 6109059 — intervention group
Group type: EXPERIMENTAL
Intervention: Hycanthone 0.75 mg/kg
Number of subjects: 0
Study 6109059 — intervention group
Group type: EXPERIMENTAL
Intervention: Hycanthone 1.5 mg/kg
Number of subjects: 0
Study 6109059 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 0
Study 31633261 — intervention group
Group type: COMPARATOR
Intervention: Accelerated sham rTMS
Number of subjects: 0
Study 31847888 — intervention group
Group type: EXPERIMENTAL
Intervention: Mission Papillagou program
Number of subjects: 520
Study 28951368 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal LSTs
Number of subjects: 52
Study 28951368 — intervention group
Group type: COMPARATOR
Intervention: LST‐NG‐PD
Number of subjects: 52
Study 28951368 — intervention group
Group type: EXPERIMENTAL
Intervention: LSTs
Number of subjects: 52
Study 26209535 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily low-dose hCG (125 IU) for luteal phase support after GnRHa trigger, initiated on stimulation day 2 or day 6.
Number of subjects: 93
Study 26209535 — intervention group
Group type: COMPARATOR
Intervention: Control group followed a standard antagonist protocol without hCG supplementation.
Number of subjects: 93
Study 24021360 — intervention group
Group type: EXPERIMENTAL
Intervention: internet-based CBT (iCBT)
Number of subjects: 84
Study 24021360 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study 19939650 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched dairy product (0.6 L/day) for 5 months
Number of subjects: 107
Study 19939650 — intervention group
Group type: COMPARATOR
Intervention: Standard whole milk (0.6 L/day) for 5 months
Number of subjects: 107
Study 19729323 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 300 mg day(-1) for 15 days (Group III)
Number of subjects: 2
Study 19729323 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-varicose veins from healthy patients, Group I)
Number of subjects: 2
Study 19729323 — intervention group
Group type: COMPARATOR
Intervention: Varicose veins (Group II, no drug treatment)
Number of subjects: 2
Study 17825692 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 880 microg IN qSh for 10 doses
Number of subjects: 16
Study 17825692 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone furoate 250 microg IV
Number of subjects: 16
Study 15145921 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine standardization
Number of subjects: 229
Study 15145921 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle mass accounting
Number of subjects: 229
Study 11260238 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% diethylenetriaminepentaacetic acid (DTPA) cream
Number of subjects: 28
Study 9027670 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (40 mg/day)
Number of subjects: 90
Study 9027670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 8312583 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention (reducing fat intake to 15-20% of total calories)
Number of subjects: 93
Study 8312583 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen adjuvant therapy
Number of subjects: 93
Study 8312583 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention (in patients not receiving tamoxifen)
Number of subjects: 93
Study 8312583 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen without dietary intervention
Number of subjects: 93
Study 8312583 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention
Number of subjects: 93
Study 8312583 — intervention group
Group type: COMPARATOR
Intervention: Dietary control group
Number of subjects: 93
Study 3520317 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 36
Study 3520317 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 36
Study 31034447 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA (FHL, 20 U; GL, 20 U)
Number of subjects: 391
Study 31034447 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Number of subjects: 391
Study 31034447 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 391
Study 28682184 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based multimedia software (self-taught DVD-Rom)
Number of subjects: 130
Study 28682184 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 130
Study 26928567 — intervention group
Group type: EXPERIMENTAL
Intervention: 200mg/kg of poractant alfa (surfactant)
Number of subjects: 118
Study 26928567 — intervention group
Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 118
Study 25005327 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 50 mg + MTX
Number of subjects: 478
Study 25005327 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 100 mg + MTX
Number of subjects: 478
Study 25005327 — intervention group
Group type: COMPARATOR
Intervention: placebo + MTX
Number of subjects: 478
Study 25005327 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab + MTX
Number of subjects: 478
Study 23252007 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydration before and after coronary angiography or angioplasty (Group A, n=40)
Number of subjects: 120
Study 23252007 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tap water before and after the procedures (Group B, n=40)
Number of subjects: 120
Study 23252007 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprocedural drinking water only (Group C, n=40)
Number of subjects: 120
Study 20422945 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of 50 mg itopride HCl
Number of subjects: 28
Study 20422945 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of 50 mg itopride HCl
Number of subjects: 28
Study 18249288 — intervention group
Group type: EXPERIMENTAL
Intervention: ClearSmile appliances (TAs)
Number of subjects: 27
Study 18249288 — intervention group
Group type: EXPERIMENTAL
Intervention: Light force (25 g)
Number of subjects: 27
Study 18249288 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy force (225 g)
Number of subjects: 27
Study 18249288 — intervention group
Group type: COMPARATOR
Intervention: Control (no force)
Number of subjects: 27
Study 16182830 — intervention group
Group type: EXPERIMENTAL
Intervention: ganciclovir
Number of subjects: 205
Study 16182830 — intervention group
Group type: COMPARATOR
Intervention: no prophylaxis
Number of subjects: 205
Study 16182830 — intervention group
Group type: COMPARATOR
Intervention: acyclovir
Number of subjects: 205
Study 16182830 — intervention group
Group type: COMPARATOR
Intervention: D-/R- group
Number of subjects: 205
Study 16182830 — intervention group
Group type: COMPARATOR
Intervention: D-/R+ group
Number of subjects: 205
Study 16182830 — intervention group
Group type: COMPARATOR
Intervention: D+/R+ group
Number of subjects: 205
Study 16182830 — intervention group
Group type: COMPARATOR
Intervention: D+/R- group
Number of subjects: 205
Study 16182830 — intervention group
Group type: COMPARATOR
Intervention: without ganciclovir prophylaxis
Number of subjects: 205
Study 16182830 — intervention group
Group type: COMPARATOR
Intervention: with infection
Number of subjects: 205
Study 12817109 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 500
Study 12817109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 11187583 — intervention group
Group type: EXPERIMENTAL
Intervention: In-patient treatment
Number of subjects: 6
Study 11187583 — intervention group
Group type: COMPARATOR
Intervention: Out-patient treatment
Number of subjects: 6
Study 8936350 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (800 mg orally three times daily for 2 years)
Number of subjects: 60
Study 8936350 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three times daily for 2 years)
Number of subjects: 60